Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Consolidated Net Income: 2018-2024

Historic Consolidated Net Income for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$45.3 million.

  • Silence Therapeutics' Consolidated Net Income rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 24.27%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
  • Latest data reveals that Silence Therapeutics reported Consolidated Net Income of -$45.3 million as of FY2024, which was up 16.45% from -$54.2 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Consolidated Net Income peaked at -$41.8 million during FY2020, and registered a low of -$59.3 million during FY2022.
  • Moreover, its 3-year median value for Consolidated Net Income was -$54.2 million (2023), whereas its average is -$52.9 million.
  • As far as peak fluctuations go, Silence Therapeutics' Consolidated Net Income plummeted by 67.16% in 2020, and later increased by 16.45% in 2024.
  • Silence Therapeutics' Consolidated Net Income (MRY) stood at -$41.8 million in 2020, then fell by 29.74% to -$54.2 million in 2021, then fell by 9.38% to -$59.3 million in 2022, then increased by 8.57% to -$54.2 million in 2023, then increased by 16.45% to -$45.3 million in 2024.
  • Its Consolidated Net Income was -$45.3 million in FY2024, compared to -$54.2 million in FY2023 and -$59.3 million in FY2022.